NZB ϫ NZW F1 hybrid (B/W) mice develop altered behavior in the elevated plus maze and novel object tasks between 6 and 12 weeks of age in parallel with lupus-like autoimmune disease. To confirm the relationship between disease progression and development of behavioral abnormalities, B/W and nonautoimmune NZW mice received chronic treatment with a soluble IFNγ receptor (sIFNγR), a treatment known to retard autoimmune disease progression, or vehicle, beginning at 6 weeks of age. After 6 weeks of treatment, elevated plus maze and novel object testing revealed that although sIFNγR treated B/W mice still differed from NZW mice, chronic sIFNγR treatment significantly retarded the development of behavioral abnormalities in the B/W mice, while the NZW mice were not affected by this treatment. sIFNγR treated B/W mice were more active in both the plus maze and novel object tasks, and displayed less plus maze anxiety behavior and more exploratory activity in the novel object task compared to vehicle treated B/W mice. To clarify the role of acute action of the sIFNγR on the elevated IFNγ levels of B/W mice, a second experiment examined the effects of a single injection of sIFNγR on B/W and NZW mice. Unlike chronic treatment, acute treatment with the same dose of sIFNγR did not affect plus maze or novel object behavior in 12-week-old mice. These results add to the growing evidence that lupus-associated behavioral abnormalities are a direct effect of the autoimmune disease.
INTRODUCTION
The autoimmune disease systemic lupus erythematosus (SLE) is often accompanied by central nervous system manifestations including neurological, cognitive, and psychiatric symptoms. In addition to massive overproduction of autoantibodies, including pathogenic anti-DNA antibodies (reviewed by Ferrell & Tan, 1985; Glass & Schur, 1977; Reichlin, 1991) , SLE is characterized by a profound dysregulation of the cytokine network that is likely involved in both disease initiation and progression. In humans circulating levels of interleukin-2 (IL -2), IL -4, IL -6, IL -10, and interferon-α (IFN-α) and -γ are increased. In mice IL -1, IL -6, IL -10, tumor necrosis factor-α (TNF -α), and IFN -α and -γ have been implicated in disease pathogenesis (Handwerger, Rus, da Silva, & Via 1994; Horwitz & Jacob, 1994) . The most consistent results involve the IFNs. In NZB or NZB-derived autoimmune mice exogenous mixed IFNs (Adam, Thoua, Ronco, Verroust, Tovey, & Morel-Maroger, 1980; Heremans, Billau, Colombatti, Hilgers, & De Somer 1978; Steinberg, Baron, & Talal, 1969) , IFN -α (Sergiescu, Cerutti, Efthymiou, Kahan, & Chany, 1979; Sergiescu, Cerutti, Kahan, Piatier, & Efthymiou, 1981) , and IFN-γ (Engleman, Sonnenfeld, Dauphinee, Greenspan, Talal, McDevitt, & Merigan, 1981; Jacob, van der Meide, & 
